(Total Views: 344)
Posted On: 09/11/2019 10:58:23 AM
Post# of 155150
from the other board
CruJones85 @
"I was reading in the pink sheet that Amgen Pharmaceuticals is looking to start focusing on using a Novel CCR5 inhibitor to advance further into the cancer space. In their portfolio, I currently do not see a CCR5 inhibitor listed. So not sure if they are developing one, or would be acquiring a CCR5 antagonist. The article I read, eluded to the fact that Amgen views CCR5 as possibly a revolutionary step in the treatment of cancers, inflammatory diseases, and other unmet medical needs. I read this in the Pink Sheet. So like I said, they could be working on development of their own CCR5 antagonist or could they be purchasing or partnering. Tomorrow should be interesting. "
CruJones85 @
"I was reading in the pink sheet that Amgen Pharmaceuticals is looking to start focusing on using a Novel CCR5 inhibitor to advance further into the cancer space. In their portfolio, I currently do not see a CCR5 inhibitor listed. So not sure if they are developing one, or would be acquiring a CCR5 antagonist. The article I read, eluded to the fact that Amgen views CCR5 as possibly a revolutionary step in the treatment of cancers, inflammatory diseases, and other unmet medical needs. I read this in the Pink Sheet. So like I said, they could be working on development of their own CCR5 antagonist or could they be purchasing or partnering. Tomorrow should be interesting. "
(1)
(0)
